Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obstacles and expectations of rare disease patients and their families in Türkiye: ISTisNA project survey results.
Hatirnaz Ng O, Sahin I, Erbilgin Y, Ozdemir O, Yucesan E, Erturk N, Yemenici M, Akgun Dogan O, Ugur Iseri SA, Satman I, Alanay Y, Ozbek U. Hatirnaz Ng O, et al. Among authors: erbilgin y. Front Public Health. 2023 Jan 4;10:1049349. doi: 10.3389/fpubh.2022.1049349. eCollection 2022. Front Public Health. 2023. PMID: 36684907 Free PMC article.
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Ongoren S, et al. Among authors: erbilgin y. Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Hematology. 2018. PMID: 28990873 Review.
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S, Tasar O, Mercan S, Sisko S, Khodzhaev K, Ongoren S, Ar MC, Baslar Z, Soysal T, Sayitoglu M, Ozbek U. Erbilgin Y, et al. Leuk Lymphoma. 2019 Jan;60(1):200-207. doi: 10.1080/10428194.2018.1473573. Epub 2018 Jul 2. Leuk Lymphoma. 2019. PMID: 29965782
Prognostic gene alterations and clonal changes in childhood B-ALL.
Erbilgin Y, Firtina S, Mercan S, Hatirnaz Ng O, Karaman S, Tasar O, Karakas Z, Celkan TT, Zengin E, Sarper N, Yildirmak ZY, Sisko S, Ozbek U, Sayitoglu M. Erbilgin Y, et al. Leuk Res. 2019 Aug;83:106159. doi: 10.1016/j.leukres.2019.05.009. Epub 2019 Jun 8. Leuk Res. 2019. PMID: 31228652 Clinical Trial.
26 results